Etanercept in RA: will it crack the early disease market?

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1221, 2000-01, pp. : 13-14

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Infliximab, etanercept worthwhile for RA in Spain?

Inpharma, Vol. 1, Iss. 1449, 2004-01 ,pp. : 5-6

Adis International

Access to resources Recommend Favorite

Global economic model needed for pharmaceutical market?

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 455, 2004-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Is early intervention with biological agents worthwhile in RA?

Inpharma, Vol. 1, Iss. 1476, 2005-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Etanercept: beneficial effects in early RA

Inpharma, Vol. 1, Iss. 1267, 2000-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite

Ustekinumab to usurp etanercept in psoriasis?

Inpharma, Vol. 1, Iss. 1658, 2008-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite